
Sign up to save your podcasts
Or


This episode explores why ASHP’s Council on Public Policy has taken a fresh approach to a longstanding question: how should pharmacists be reimbursed for cognitive services? Joining the conversation are the council’s secretary and a former member who is also a health-system leader. They break down the newly adopted Policy 2506, Payment Parity for Pharmacists’ Services, discuss what it aims to accomplish for practicing pharmacists, and examine the broader implications if progress is achieved. The episode unpacks why policy language matters, traces the evolution of ASHP’s stance on pharmacist payment parity, and explores how the new policy could help advance this critical issue.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
By American Society of Health-System Pharmacists©4.5
3737 ratings
This episode explores why ASHP’s Council on Public Policy has taken a fresh approach to a longstanding question: how should pharmacists be reimbursed for cognitive services? Joining the conversation are the council’s secretary and a former member who is also a health-system leader. They break down the newly adopted Policy 2506, Payment Parity for Pharmacists’ Services, discuss what it aims to accomplish for practicing pharmacists, and examine the broader implications if progress is achieved. The episode unpacks why policy language matters, traces the evolution of ASHP’s stance on pharmacist payment parity, and explores how the new policy could help advance this critical issue.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

5,111 Listeners

1,865 Listeners

318 Listeners

499 Listeners

25,857 Listeners

3,348 Listeners

112,918 Listeners

259 Listeners

56,544 Listeners

1,156 Listeners

733 Listeners

196 Listeners

16,241 Listeners

161 Listeners

251 Listeners